Our partnership with Dr. Glaucomflecken continues as he summarizes the final, 10-year outcomes of the CheckMate 067 trial, which investigated nivolumab plus ipilimumab in advanced melanoma. Access the article for free:

@DGlaucomflecken Shouldn’t a medical oncologist be discussing this study rather than a dermatologist?

An estimated $30 Billion has been set aside in asbestos trust funds for victims of mesothelioma and other asbestos-related cancers. Submit the simple form below or call 866-269-3435 to file a claim now.

@DGlaucomflecken It's australian 😁 yeah we do tend to need stronger sunscreen here.

@DGlaucomflecken Brilliant. Please continue this collaboration!

@DGlaucomflecken Melanoma is a hot tumor with high mutational burden, making it the most susceptible to I/O therapy.

@DGlaucomflecken It's a real paper 😁

@DGlaucomflecken 💕 the partnership 🤩 Next 👉🏽 #Trastuzumab for #HER2 low patients, such a 🔥 topic @TheUSCAP #Pathology annual meeting #USCAP2025

@DGlaucomflecken Genius Vid

@DGlaucomflecken I wish all the papers were summarized for us like this xD @DGlaucomflecken goat

@DGlaucomflecken @DGlaucomflecken is amazing as usual..so good that I am going to the #ELCC25 @myESMO by 🚊 and I am tempted to but on sun cream